Strs Ohio Makes New Investment in QIAGEN N.V. $QGEN

Strs Ohio purchased a new stake in QIAGEN N.V. (NYSE:QGEN) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 47,110 shares of the company’s stock, valued at approximately $1,891,000.

Several other large investors have also modified their holdings of the business. Exchange Traded Concepts LLC raised its stake in shares of QIAGEN by 2.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company’s stock worth $716,000 after acquiring an additional 395 shares in the last quarter. SVB Wealth LLC bought a new position in shares of QIAGEN during the 1st quarter worth approximately $31,000. Walleye Trading LLC raised its stake in shares of QIAGEN by 14.6% during the 1st quarter. Walleye Trading LLC now owns 7,367 shares of the company’s stock worth $296,000 after acquiring an additional 936 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of QIAGEN by 14.4% during the 4th quarter. Cetera Investment Advisers now owns 11,297 shares of the company’s stock worth $505,000 after acquiring an additional 1,418 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after acquiring an additional 1,425 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on QGEN shares. Bank of America boosted their price objective on shares of QIAGEN from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, June 26th. Cowen reissued a “hold” rating on shares of QIAGEN in a research report on Thursday, August 7th. UBS Group boosted their target price on shares of QIAGEN from $48.00 to $50.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Wall Street Zen downgraded shares of QIAGEN from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 11th. Finally, Barclays began coverage on shares of QIAGEN in a research report on Tuesday, June 24th. They set an “overweight” rating and a $55.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, QIAGEN has an average rating of “Hold” and an average price target of $49.69.

QIAGEN Stock Up 0.5%

QGEN stock opened at $45.60 on Wednesday. The firm’s fifty day simple moving average is $48.38 and its 200-day simple moving average is $44.73. QIAGEN N.V. has a 12 month low of $37.63 and a 12 month high of $51.88. The company has a market capitalization of $10.14 billion, a P/E ratio of 26.94, a price-to-earnings-growth ratio of 2.40 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35.

QIAGEN (NYSE:QGEN) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.60. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The firm had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. During the same period in the prior year, the firm posted $0.55 earnings per share. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, equities research analysts forecast that QIAGEN N.V. will post 2.26 earnings per share for the current year.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.